Erythropoietic growth factors for children with cancer: A systematic review of the literature

Current Medical Research and Opinion

Volumn 23, Issue 11, 2007, Pages 2841-2847

  Mystakidou, Kyriaki ^a   Potamianou, Anna ^b   Tsilika, Eleni ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

Author keywords

Anaemia; Erythropoiesis; Erythropoietin; Oncology; Paediatrics

Indexed keywords

CISPLATIN; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRON; MAFOSFAMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; HUMAN; IRON INTAKE; NEUROBLASTOMA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SARCOMA; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANEMIA; CHILD; ERYTHROPOIETIN, RECOMBINANT; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEUROBLASTOMA;

EID: 36348963635     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242601     Document Type: Review

References (25)

1. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14
2. Michon J. Incidence of anemia in pediatric cancer patients in Europe: results of a large, international survey. Med Pediatr Oncol 2002;39:448-50
3. Ruggiero A, Riccardi R. Interventions for anemia in pediatric cancer patients. Med Pediatr Oncol 2002;39:451-4
4. Donato H. Erythropoietin: an update on the therapeutic use in newborn infants and children. Expert Opin Pharmacother 2005;6:723-34
5. Feusner J, Hastings C. Recombinant human erythropoietin in pediatric oncology: a review. Med Pediatr Oncol 2002;39:463-8
6. Guyot D, Margueritte G. Utilisation de l'érythropoïé tine recombinante humaine chez l'enfant atteint de cancer [Use of human recombinant erythropoietin in children with cancer]. Arch Pediatr 2005;12:1376-82
7. Parsons SK. Oncology practice patterns in the use of hematopoietic growth factors. Curr Opin Pediatr 2000;12:10-7
8. Csáki C, Ferencz T, Schuler D, Borsi JD. Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumours. Eur J Cancer 1998;34:364-7
9. Porter JC, Leahey A, Polise K, et al. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. J Pediatr 1996;129:656-60
10. Razzouk BI, Hord JD, Hockenberry M, et al. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol 2006;24:3583-9
11. Varan A, Buyukpamukcu M, Kutluk T, Akyuz C. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics 2006;103:E16
12. Wagner LM, Billups CA, Furman WL, et al. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J Clin Oncol 2004;22:1886-93
13. Bolonaki I, Stiakaki E, Lydaki E, et al. Treatment with recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol 1996;13:111-21
14. León P, Jiménez M, Barona P, Sierrasesúmaga L. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol 1998;30:110-6
15. Locatelli F, Zecca M, Pedrazzoli P, et al. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 1994;13:403-10
16. Tenenbaum T, Hasan C, Kramm CM, et al. Oncological management of pediatric cancer patients belonging to Jehovah's Witnesses: a two-institutional experience report. Onkologie 2004;27:131-7
17. Yilmaz D, Cetingul N, Kantar M, et al. A single institutional experience: is epoetin alpha effective in anemic children with cancer? Pediatr Hematol Oncol 2004;21:1-8
18. Zoubek A, Kronberger M. Early epoetin alfa treatment in children with solid tumors. Med Pediatr Oncol 2002;39:459-62
19. Beck MN, Beck D. Recombinant erythropoietin in acute chemotherapy-induced anemia of children with cancer. Med Pediatr Oncol 1995;25:17-21
20. Cascinu S, Fedeli A, Del Ferro E, et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994;12:1058-62
21. Case DC, Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993;85:801-6
22. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2007;19:2865-74
23. Del Mastro L, Venturini M, Lionetto R, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 2007;15:2715-21
24. Sinclair AM, Todd MD, Forsythe K, et al. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007;110:477-88
25. Osterborg A, Aapro M, Cornes P, et al. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 2007;43:510-9